ClinicalTrials.gg
CompletedNCT06859476Updated Apr 8, 2026Results posted

Evaluation of Manzanilla® and Meticel Ofteno® 0.5% for Providing a Relief Sensation to the Eyes

A Phase 4 interventional study of Manzanilla Sophia® and Meticel Ofteno® 0.5% in Ophthalmological Agent Toxicity, sponsored by Laboratorios Sophia S.A de C.V.. Completed at 1 site in Mexico. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-04-08.

Sponsored by Laboratorios Sophia S.A de C.V. · Phase 4, Interventional, and Other

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
167
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

Demonstrate the non-inferiority of Manzanilla Sophia® compared to Meticel Ofteno® 0.5% in providing a sensation of eye relief, through the score of an analogous visual test for eye fatigue.

Read the detailed description

Primary Objective:

Demonstrate the non-inferiority of Manzanilla Sophia® compared to Meticel Ofteno® 0.5% in providing a sensation of eye relief, through the score of an analogous visual test for eye fatigue.

Secondary Objectives:

Signs and Symptoms Evaluated:

  • Compare Manzanilla Sophia® to Meticel Ofteno® 0.5% in the incidence of red eye.
  • Compare Manzanilla Sophia® to Meticel Ofteno® 0.5% in the incidence of dry eye sensation.
  • Compare Manzanilla Sophia® to Meticel Ofteno® 0.5% in the incidence of eye irritation.
  • Compare Manzanilla Sophia® to Meticel Ofteno® 0.5% in the incidence of sensation of eye discharge (sleep).
  • Compare Manzanilla Sophia® to Meticel Ofteno® 0.5% in the incidence of comfort with the application of the investigational product (IP).

Safety Assessment:

- Compare the incidence of adverse events (AEs) related to the interventions.

02

Conditions studied

  • Ophthalmological Agent Toxicity

Keywords

  • Matricaria Recutita
03

In context

Lead sponsor

Laboratorios Sophia S.A de C.V. is the lead sponsor of 45 studies on the registry; 5 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Ability to voluntarily provide signed .
  • Able and willing to comply with the scheduled visits, treatment plan, and other study procedures.
  • Be of legal age.
  • Women of reproductive age who have not undergone bilateral tubal ligation or hysterectomy must ensure the continued use (initiated ≥ 30 days prior to signing the - - Informed Consent Form [ICF]) of a hormonal method or intrauterine device (IUD) during the study period.
  • A score of ≥ 3 on the analogous visual test for eye fatigue in at least 4 of the included questions.

Exclusion criteria

Exclusion Criteria:

  • Pregnant women, breastfeeding women, or those planning to become pregnant during the study period.
  • Having participated in another clinical research study ≤ 30 days prior to the screening visit.
  • Having previously participated in this study.
  • Having only one functional eye.
  • A history of current or past drug addiction or substance dependence within the last two years prior to signing the ICF.
  • Current user of soft or hard contact lenses. They may be included if they suspend use during the study, and they must be lens-free for 15 days prior to inclusion.
  • Known to the components of the products.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 4
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
167 participants (actual)

Study arms

  • Experimental
    Manzanilla Sophia®

    Matricaria recutita 0.025%. One drop four times per day (QID), with a minimun interval of 3 hours between administrations, for 7 days.

    Drug: Manzanilla Sophia®

  • Active comparator
    Meticel Ofteno® 0.5%

    Hydroxypropyl methylcellulose 0.5%. One drop QID, with a minimun interval of 3 hours between administrations, for 7 days.

    Drug: Meticel Ofteno® 0.5%

Interventions

  • DrugManzanilla Sophia®

    Ophthalmic solution. Laboratorios Sophia, S.A. de C.V., Zapopan, Jalisco, Mexico. Route of Administration: Ophthalmic.

  • DrugMeticel Ofteno® 0.5%

    Ophthalmic solution. Laboratorios Sophia, S.A. de C.V., Zapopan, Jalisco, Mexico. Route of Administration: Ophthalmic.

06

What researchers measure

Primary outcomes

  1. The Proportion of Participants Who Decreased ≥ 6 Points or the Equivalent of 20% or More in the Visual Analog Test Score Compared to Their Baseline

    To demonstrate the non-inferiority of Manzanilla Sophia® compared to Meticel Ofteno® 0.5% in providing a sensation of eye relief, through the score of an analogous visual test for eye fatigue. Based on other tools previously used for the assessment of eye fatigue, the visual analog test for eye fatigue used in this protocol is adapted and created. This test includes the following questions: "Have you had a headache?", "Have you had eye strain?", "Do you have gritty sensation in your eyes?", "Have your eyes been itchy?", "How would you describe your clarity of sight?", "Do you feel any discomfort when you fix your eyes?". Each of these questions will be answered according to a Likert scale of 1-5. The sum of the answers, the total score, will be measured in a scale from 6 to 30. A higher score is a a worse outcome for this variable.

    Time frame: Day 8 (Final visit)

Secondary outcomes

  1. Comparison of Manzanilla Sophia® and Meticel Ofteno® 0.5% in the Incidence of Red Eye

    The presence of red eye (presence/absence) will be assessed based on direct observation by the investigator.

    Time frame: Day 0 (Basal visit), Day 8 (Final visit)

  2. Comparison of Manzanilla Sophia® and Meticel Ofteno® 0.5% in the Incidence of Dry Eye Sensation.

    This symptom was obtained by direct questioning of the subject by the principal investigator, and the response was recorded as present/absent.

    Time frame: Day 0 (Basal visit), Day 8 (Final visit)

  3. Comparison of Manzanilla Sophia® and Meticel Ofteno® 0.5% in the Incidence of Eye Irritation

    This symptom was obtained by direct questioning of the subject by the principal investigator, and the response was recorded as present/absent.

    Time frame: Day 0 (Basal visit), Day 8 (Final visit)

  4. Comparison of Manzanilla Sophia® and Meticel Ofteno® 0.5% in the Incidence of Sensation of Eye Discharge.

    This symptom was obtained by direct questioning of the subject by the principal investigator, and the response was recorded as present/absent.

    Time frame: Day 0 (Basal visit), Day 8 (Final visit)

  5. Comparison of Manzanilla Sophia® and Meticel Ofteno® 0.5% in the Incidence of Comfort With the Application of the Investigational Product (IP).

    This result was obtained by the principal investigator directly questioning the subject, and the response was recorded as present/absent.

    Time frame: Day 8 (Final visit)

Other outcomes

  1. Comparison of the Incidence of Adverse Events (AEs) Related to the Interventions Between Groups

    For this variable, only the number of adverse events classified as related to interventions in each group are compared.

    Time frame: Day 0 (Basal visit), Day 8 (Final visit)

07

Results

Posted Apr 8, 2026

Participant flow

Participant flow — Overall Study
MilestoneManzanilla Sophia®Meticel Ofteno® 0.5%
Started8483
Completed8381
Not completed12

Outcome measures

PrimaryThe Proportion of Participants Who Decreased ≥ 6 Points or the Equivalent of 20% or More in the Visual Analog Test Score Compared to Their Baseline

To demonstrate the non-inferiority of Manzanilla Sophia® compared to Meticel Ofteno® 0.5% in providing a sensation of eye relief, through the score of an analogous visual test for eye fatigue. Based on other tools previously used for the assessment of eye fatigue, the visual analog test for eye fatigue used in this protocol is adapted and created. This test includes the following questions: "Have you had a headache?", "Have you had eye strain?", "Do you have gritty sensation in your eyes?", "Have your eyes been itchy?", "How would you describe your clarity of sight?", "Do you feel any discomfort when you fix your eyes?". Each of these questions will be answered according to a Likert scale of 1-5. The sum of the answers, the total score, will be measured in a scale from 6 to 30. A higher score is a a worse outcome for this variable.

Time frame:
Day 8 (Final visit)
Reported as:
Count of participants · Participants
The Proportion of Participants Who Decreased ≥ 6 Points or the Equivalent of 20% or More in the Visual Analog Test Score Compared to Their Baseline
ParticipantsManzanilla Sophia®Meticel Ofteno® 0.5%
The Proportion of Participants Who Decreased ≥ 6 Points or the Equivalent of 20% or More in the Visual Analog Test Score Compared to Their Baseline7472
Statistical analysis
  • Manzanilla Sophia® vs Meticel Ofteno® 0.5% · Chi-squared · Difference of proportions: 0.05The non-inferiority hypothesis was assessed according to the protocol and the statistical analysis plan for the primary variable.
SecondaryComparison of Manzanilla Sophia® and Meticel Ofteno® 0.5% in the Incidence of Red Eye

The presence of red eye (presence/absence) will be assessed based on direct observation by the investigator.

Time frame:
Day 0 (Basal visit), Day 8 (Final visit)
Reported as:
Count of participants · Participants
Comparison of Manzanilla Sophia® and Meticel Ofteno® 0.5% in the Incidence of Red Eye
ParticipantsManzanilla Sophia®Meticel Ofteno® 0.5%
Basal visit — Red eye159
Basal visit — No red eye6872
Final visit — Red eye11
Final visit — No red eye8280
SecondaryComparison of Manzanilla Sophia® and Meticel Ofteno® 0.5% in the Incidence of Dry Eye Sensation.

This symptom was obtained by direct questioning of the subject by the principal investigator, and the response was recorded as present/absent.

Time frame:
Day 0 (Basal visit), Day 8 (Final visit)
Reported as:
Count of participants · Participants
Comparison of Manzanilla Sophia® and Meticel Ofteno® 0.5% in the Incidence of Dry Eye Sensation.
ParticipantsManzanilla Sophia®Meticel Ofteno® 0.5%
Basal visit5355
Final visit108
SecondaryComparison of Manzanilla Sophia® and Meticel Ofteno® 0.5% in the Incidence of Eye Irritation

This symptom was obtained by direct questioning of the subject by the principal investigator, and the response was recorded as present/absent.

Time frame:
Day 0 (Basal visit), Day 8 (Final visit)
Reported as:
Count of participants · Participants
Comparison of Manzanilla Sophia® and Meticel Ofteno® 0.5% in the Incidence of Eye Irritation
ParticipantsManzanilla Sophia®Meticel Ofteno® 0.5%
Basal visit5454
Final visit138
SecondaryComparison of Manzanilla Sophia® and Meticel Ofteno® 0.5% in the Incidence of Sensation of Eye Discharge.

This symptom was obtained by direct questioning of the subject by the principal investigator, and the response was recorded as present/absent.

Time frame:
Day 0 (Basal visit), Day 8 (Final visit)
Reported as:
Count of participants · Participants
Comparison of Manzanilla Sophia® and Meticel Ofteno® 0.5% in the Incidence of Sensation of Eye Discharge.
ParticipantsManzanilla Sophia®Meticel Ofteno® 0.5%
Basal visit3238
Final visit42
SecondaryComparison of Manzanilla Sophia® and Meticel Ofteno® 0.5% in the Incidence of Comfort With the Application of the Investigational Product (IP).

This result was obtained by the principal investigator directly questioning the subject, and the response was recorded as present/absent.

Time frame:
Day 8 (Final visit)
Reported as:
Count of participants · Participants
Comparison of Manzanilla Sophia® and Meticel Ofteno® 0.5% in the Incidence of Comfort With the Application of the Investigational Product (IP).
ParticipantsManzanilla Sophia®Meticel Ofteno® 0.5%
Comparison of Manzanilla Sophia® and Meticel Ofteno® 0.5% in the Incidence of Comfort With the Application of the Investigational Product (IP).7368
Other pre-specifiedComparison of the Incidence of Adverse Events (AEs) Related to the Interventions Between Groups

For this variable, only the number of adverse events classified as related to interventions in each group are compared.

Time frame:
Day 0 (Basal visit), Day 8 (Final visit)
Reported as:
Number · number of events
Comparison of the Incidence of Adverse Events (AEs) Related to the Interventions Between Groups
number of eventsManzanilla Sophia®Meticel Ofteno® 0.5%
Related4845
Unrelated34

Adverse events

Collected over The adverse events were recorded over an 11-day period, the duration of the clinical study.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Manzanilla Sophia®0/84 (0%)0/84 (0%)35/84 (41.7%)
Meticel Ofteno® 0.5%0/83 (0%)0/83 (0%)35/83 (42.2%)
Most frequent other events
Showing 10 of 15
Most frequent other events
EventManzanilla Sophia®Meticel Ofteno® 0.5%
Eye irritationEye disorders26/8423/83
Itching in the eyeEye disorders9/847/83
Blurred visionEye disorders3/847/83
Increased tearingEye disorders4/841/83
HeadacheNervous system disorders4/841/83
AsthenopiaEye disorders0/842/83
Nasal congestionRespiratory, thoracic and mediastinal disorders0/842/83
Eye painEye disorders2/841/83
DysgeusiaNervous system disorders1/841/83
DengueInfections and infestations0/841/83

Baseline characteristics

Demographic characteristics were analyzed in the intention-to-treat (ITT) population.

Age, Continuous
Age, Continuous(years)Manzanilla Sophia®Meticel Ofteno® 0.5%Total
Mean42.79 ± 15.041.91 ± 14.142.69 ± 14.8
Sex: Female, Male
Sex: Female, Male(Participants)Manzanilla Sophia®Meticel Ofteno® 0.5%Total
Female5354107
Male312859
Race and Ethnicity Not Collected
Race and Ethnicity Not Collected(Participants)Manzanilla Sophia®Meticel Ofteno® 0.5%Total
Count of participants——0
Region of Enrollment
Region of Enrollment(Participants)Manzanilla Sophia®Meticel Ofteno® 0.5%Total
Mexico8482166
Systolic blood pressure
Systolic blood pressure(millimeters of mercury (mmHg))Manzanilla Sophia®Meticel Ofteno® 0.5%Total
Mean112.77 ± 14.2111.48 ± 11.2112.18 ± 12.8
Diastolic blood pressure
Diastolic blood pressure(millimeters of mercury (mmHg))Manzanilla Sophia®Meticel Ofteno® 0.5%Total
Mean71.58 ± 7.471.05 ± 7.071.28 ± 7.2
Heart rate
Heart rate(beats per minute)Manzanilla Sophia®Meticel Ofteno® 0.5%Total
Mean73.64 ± 10.272.60 ± 10.673.04 ± 10.4
Respiratory rate
Respiratory rate(breaths per minute)Manzanilla Sophia®Meticel Ofteno® 0.5%Total
Mean18.1 ± 1.517.91 ± 1.617.98 ± 1.5

2 further baseline measures are reported on the registry.

08

Study locations

1 site
  • Unidad Clinica de Bioequivalencia (UNEBI), S de R.L de C.V.
    Guadalajara, Jalisco, Mexico
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from May 2025 to primary completion in Sep 2025, 4 months.

Results were first posted in Apr 2026, 6 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 27, 2025
First posted
Mar 5, 2025
StartActual
May 23, 2025
Primary completionActual
Sep 23, 2025
CompletionActual
Sep 23, 2025
Results first posted
Apr 8, 2026
Last update
Apr 8, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 8, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT06859476
Responsible party
Sponsor
First posted
Mar 5, 2025
Start date
May 23, 2025
Primary completion
Sep 23, 2025
Completion
Sep 23, 2025
Results posted
Apr 8, 2026
Last update
Apr 8, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion